References
- Turnbull, D. Undercooled Alloy Phases; Metallurgical Soc.: Warendale, PA, 1986; 3–22.
- Zarzycki, J. Glasses and the Vitreous State; Cambridge University Press: Cambridge, 1990.
- Hancock, B.C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems.J. Pharm. Sci. 1997, 86 (1), 1–12., [PUBMED], [INFOTRIEVE]
- Guillory, J.K. Swarbrick, JGeneration of polymorphs, hydrates, solvates, and amorphous solids. In Polymorphism in Pharmaceutical Solids; ., Ed.; Marcel Dekker, Inc.: New York, 1999; 183–226.
- Nanda, A.R.; Rowlings, C.E.; Barker, N.P.; Sheen, P.-C. Liu, RImmediate release solid dispersions for oral drug delivery. In Water-Insoluble Drug Formation; ., Ed.; Interpharm Press: Englewood, 2000; 493–523.
- Hancock, B.C. Disordered drug delivery: destiny, dynamics and the Deborah number.J. Pharm. Pharmacol. 2002, 54 (6), 737–746., [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nielsen, F. Spray drying pharmaceuticals.Manu. Chem. 1982, 53 (7), 38–41.
- Broadhead, J.; Rouan, S.K.E.; Rhodes, C.T. The spray drying of pharmaceuticals.Drug Dev. Ind. Pharm. 1992, 18 (11 & 12), 1169–1206.
- Masters, K. Spray Drying Handbook; , Longman (UK) & John Wiley & Sons (USA), 1985.
- Chawla, G.; Gupta, P.; Thilagavathi, R.; Chakraborti, A.K.; Bansal, A.K. Characterization of solid-state forms of celecoxib.Eur. J. Pharm. Sci. 2003, 20 (3), 305–317., [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bansal, A.K.Gupta, P.Kakumanu, V.K. A Synergistic Pharmaceutical Composition of Celecoxib with Improved Aqueous Solubility. Indian Complete Patent Application No. 685/Del/2002, 2002.
- United States Pharmacopeia USP 26/National Formulary 21; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2003.
- Gupta, P.; Kakumanu, V.K.; Bansal, A.K. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.Pharm. Res. 2004, 21 (10), 1762–1769., [PUBMED], [INFOTRIEVE], [CROSSREF]
- Saha, R.N.; Sajeev, C.; Jadhav, P.R.; Patil, S.P.; Srinivasan, N. Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography.J. Pharm. Biomed. Anal. 2002, 28 (3–4), 741–751., [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dhabu, P.M.; Akamanchi, K.G. A stability-indicating HPLC method to determine celecoxib in capsuleformulations.Drug Dev. Ind. Pharm. 2002, 28 (7), 815–821., [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hageman, M.J.; Miyake, P.J.; Stefanski, K.J.; He, X.; Rohrs, B.R.; Mackin, L.A.; Kararli, T.T. Solid-state form of celecoxib having enhanced bioavailability. 2001, , WO0141536.
- Celebrex, 2004, , www.celebrex.com (accessed Sept. 2004).
- Weller, P.J. Kibbe, A.HMeglumine. In Handbook of Pharmaceutical Excipients, 3rd Ed.; ., Ed.; American Pharmaceutical Association: Washington, DC, 2000; 332–333.
- Meglumine. Inactive Ingredients Guide. FDA/Centre for Drug Evaluation and Research, 2004. , www.fda.gov/cder/iig, (accessed Sept. 2004).
- The European Agency for the Evaluation of Medicinal Products—CPMP/1361/00, 2000. , www.emea.eu.int, (accessed Sept. 2004).